AbbVie (NYSE:ABBV) Trading Down 1.7% – What’s Next?

AbbVie Inc. (NYSE:ABBV)’s stock price fell 1.7% on Thursday . The company traded as low as $228.00 and last traded at $232.07. 9,390,226 shares traded hands during trading, an increase of 29% from the average session volume of 7,270,855 shares. The stock had previously closed at $236.19.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 AFFIRM results for risankizumab in moderately‑to‑severe Crohn’s disease boost AbbVie’s immunology growth outlook and support valuation upside as investors reassess long‑term revenue for the drug. Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results
• Positive Sentiment: AbbVie opened a new Phase 2 study of venetoclax in rare blood cancers (Japan), extending its oncology footprint and adding upside optionality if early signals prove meaningful. AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) highlighted medical weight‑loss adoption and shifting patient demand, supporting the aesthetics revenue runway and diversification of AbbVie’s commercial portfolio. ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA
• Positive Sentiment: Coverage pieces and investor commentary note AbbVie’s strong free‑cash‑flow profile and sizable dividend, which underpin investor confidence despite heavy R&D and M&A activity. (Market commentary)
• Neutral Sentiment: AbbVie completed a large senior‑notes offering (reported at $8B/$7.5B in different releases). The debt sale increases leverage but also provides liquidity for refinancing, buybacks, or acquisitions—a mixed signal for investors. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Neutral Sentiment: Technical/market commentary indicates ABBV is “stabilizing near $233” while testing resistance levels—useful for short‑term traders but not a fundamental catalyst on its own. AbbVie: Stabilizes Near $233 While Testing Resistance
• Neutral Sentiment: AbbVie’s presentation at the TD Cowen healthcare conference provided updated management commentary (transcript available) — more detail for analysts but no single market‑moving surprise. AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Negative Sentiment: AbbVie lost a bid to block Tennessee’s 340B law, a legal setback that could pressure pricing/reimbursement dynamics in certain channels and raises policy‑risk concerns for investors focused on drug pricing exposure. AbbVie loses bid to block Tennessee 340B law

Analyst Ratings Changes

Several brokerages recently commented on ABBV. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. UBS Group cut their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Citigroup decreased their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Piper Sandler lifted their target price on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Finally, Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Price Performance

The stock has a 50-day moving average price of $224.68 and a 200-day moving average price of $223.75. The company has a market capitalization of $410.34 billion, a price-to-earnings ratio of 98.33, a PEG ratio of 0.81 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.25% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AbbVie

A number of hedge funds have recently added to or reduced their stakes in the stock. Chelsea Counsel Co. bought a new position in shares of AbbVie in the 3rd quarter valued at $26,000. Litman Gregory Wealth Management LLC acquired a new position in AbbVie in the 4th quarter worth about $28,000. Imprint Wealth LLC raised its position in AbbVie by 56.3% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the last quarter. Westend Capital Management LLC acquired a new stake in shares of AbbVie during the fourth quarter valued at about $29,000. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of AbbVie during the fourth quarter valued at about $31,000. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.